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TO THE EDITOR
The shape of the mitochondrial network
results from the cumulative activity of
two opposing processes: fusion and
ﬁssion (Mishra and Chan, 2014). These
processes collaborate to ensure homeo-
static maintenance of mitochondrial
function, cellular bioenergetics, and
commitment to mitosis (Nasrallah and
Horvath, 2014). Although the contribu-
tions of aberrant mitochondrial dyna-
mics in neurodegenerative and cardio-
metabolic diseases are established, little
is known about the contribution of mito-
chondrial dynamics in cancer develop-
ment, prognosis, or treatment.
Recently, a role for dynamin-related
protein 1 (DRP1) was revealed in
oncogenic rat sarcoma-induced cellular
transformation and in cellular responses to
oncogenic mitogen-activated protein
kinase (MAPK) inhibition (e.g., BRAFV600E
(v-Raf murine sarcoma viral oncogene
homolog B) inhibition with PLX-4032)
(Bollag et al., 2010; Serasinghe et al.,
2015). DRP1 is a large cytosolic
guanosine-5′-triphosphosphatase that
induces ﬁssion of the mitochondrial
network (Yoon et al., 2001; Smirnova
et al., 2001). For example, when DRP1 is
phosphorylated at serine 616
(DRP1S616℗), DRP1 localizes to mito-
chondria, undergoes oligomerization,
and initiates membrane scission (Mishra
and Chan, 2014). DRP1S616℗ is directly
induced by ERK1/2 (extracellular signal-
regulated kinase) within the BRAFV600E
pathway leading to chronic mitochondrial
ﬁssion, cancer-associated mitochondrial
dysfunction, and resistance to targeted
therapies (Serasinghe et al., 2015). In
melanoma, DRP1S616℗ status dicho-
tomized wild-type BRAF (BRAFWt) from
BRAFV600E disease, suggesting a mechan-
istic contribution of DRP1S616℗ in
BRAFV600E melanoma (Serasinghe et al.,
2015). On the basis of these observations,
we were interested in determining
whether DRP1S616℗ was prevalent in all
BRAFV600E skin lesions (e.g., nevi) or
whether DRP1S616℗ was indicative of
BRAFV600E melanoma.
To investigate this question, we per-
formed immunohistochemistry for the
BRAFV600E and DRP1S616℗ status on a
cohort of tissues. Benign nevi (68
samples; Figure 1a and Supplementary
Figure S1a online), dysplastic nevi (40Accepted article preview online 1 June 2015; published online 18 June 2015
Abbreviations: BRAF, v-Raf murine sarcoma viral oncogene homolog B; DRP1, dynamin related protein 1;
ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase
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samples; Figure 1b and Supplementary
Figure S1b online), primary melanomas
(187 samples; Figure 1c and Supple-
mentary Figure S1c online), and
nevi derived from patients eventually
diagnosed with melanoma (46 sets;
Figure 1d) were stained. BRAFV600E
and DRP1S616℗ scoring methods were
developed (0, 1+= negative; 2+,
3+= positive) based on standard histo-
pathological analyses within the Mount
Sinai Medical Center and relevant
literature (Supplementary Figures S1a–c
online; Pearlstein et al., 2014;
Serasinghe et al., 2015). As control, we
examined tissues stained with no
primary antibody and rabbit IgG to
ensure speciﬁcity (Supplementary
Figures S2a–d and S3a–b online); and
we also examined total DRP1, which
was minimally expressed in normal skin,
benign nevi, BRAFWt melanoma, and
BRAFV600E melanoma (Supplementary
Figures S2a–d and S3a–b online).
Our benign nevi collection demon-
strated no dysplasia at the time of
diagnosis, had no known relationship
to melanoma, and DRP1S616℗ was not
signiﬁcantly related to BRAF status
(Figure 1a). Although melanoma pro-
gression is not absolutely understood,
dysplastic nevi are often considered
precursors to disease and increase the
risk of developing melanoma (Goldstein
and Tucker, 2013). Indeed, analysis
of a dysplastic nevi collection from
the Mount Sinai Dermatopathology
Division, which contained a subset of
tissues derived from patients eventually
diagnosed with melanoma, revealed
that ~ 79.3% (23/29 cases) of tissues
that are DRP1S616℗ positive are also
BRAFV600E, and 92% (23/25 cases) of
BRAFV600E dysplastic nevi display
DRP1S616℗ (Figure 1b). Within the
melanoma panel (59 BRAFWt and 128
BRAFV600E), we observed DRP1S616℗ in
91 samples; the vast majority (87/91
cases, 95.6%) were in BRAFV600E
tumors (Figure 1c). In contrast, only
four out of 59 BRAFWt tumors were
positive for DRP1S616℗. Fisher’s exact
(Po0.0001) and χ2 (Po0.0001) ana-
lyses revealed that these relationships
are highly signiﬁcant. We also analyzed
an additional larger cohort of nevi
(containing benign and dysplastic) that
are all matched to patients with mela-
noma, and similar relationships were
obtained (Figure 1d). Together, these
data suggest that DRP1S616℗ is signiﬁ-
cantly related to BRAFV600E status in
dysplastic nevi and human melanoma,
with correlations most striking in
BRAFV600E melanoma.
Literature and the above data sug-
gest that DRP1S616℗ may contribute
to the survival of BRAFV600E disease
(Serasinghe et al., 2015). Indeed,
silencing oncogenic MAPK signaling
via the pharmacological inhibition of
BRAFV600E or MAPK/ERK kinase (with
PLX-4032 or GSK-1120212, respec-
tively) decreased DRP1S616℗ by western
blot and immunoﬂuorescence, but not
DRP1Total, in BRAFV600E melanoma
cells (Figure 2a and Supplementary
Figure S4a online). The oncogenic
MAPK pathway often re-activates fol-
lowing the inhibition of BRAFV600E or
MAPK/ERK kinase, and this confounds
interpreting a direct pro-survival role for
DRP1S616℗ (Holderﬁeld et al., 2014).
Therefore, we examined DRP1S616℗
contributions in the proliferation and
survival of BRAFV600E melanoma
cell lines by DRP1 loss-of-function
experiments using RNAi and a small
molecule (mDIVI-1) that durably inhi-
bits mitochondrial ﬁssion by blocking
the DRP1 guanosine-5′-triphosphospha-
tase (Cassidy-Stone et al., 2008). A375
cells were infected with RNAi lentivirus
against Drp1 and monitored for
proliferation. Loss of Drp1 expression
correlated with decreased proliferation
and clonogenic survival (Figure 2b–e).
Next, A375 cells were treated with
mDIVI-1, evaluated by ﬂuorescent
microscopy for expected changes to
mitochondrial shape (i.e., mitochon-
drial fusion=DRP1 inhibition), and
then scored for apoptotic responses.
Indeed, the inhibition of DRP1 function
by mDIVI-1 led to a marked decrease in
DRP1-dependent mitochondrial ﬁssion
(Figure 2f) and dose-dependent apop-
tosis (Figure 2g). In contrast, the BRAFWt
melanoma line MeWo displayed
minimal DRP1S616℗ and blunted pro-
apoptotic responses to mDIVI-1 treat-
ment (Supplementary Figure S5a–b
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Figure 1. Increased DRP1S616℗ is associated with the incidence of BRAFV600E melanoma. (a–d)
Immunohistochemistry was performed to detect the status of BRAFV600E and DRP1S616℗ in benign nevi (68
samples, a), dysplastic nevi (40 samples, b), primary melanoma (187 samples, c), and nevi from patients
that developed melanoma (46 samples, d). Fisher’s exact and χ2-tests determined statistical signiﬁcance.
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online). We also treated these cells with
staurosporine to ensure that they had
intact pro-apoptotic signaling (Supple-
mentary Figure S5c online).
Altogether, these data suggest that the
induction of DRP1S616℗ in dysplastic
nevi (and nevi derived from patients
eventually diagnosed with melanoma)
and primary melanoma is a potential
contributing factor to BRAFV600E dis-
ease; and examining DRP1S616℗ status
may be a useful progression biomarker
along with BRAFV600E to determine
which lesions are most likely to develop
into disease. DRP1S616℗ is undetectable
in normal skin, and the frequency
of genomic alterations to DRP1 is
only ~ 10% in cancer (Supplementary
Figures S2a–b and S6a–b online;
Cerami et al., 2012; Gao et al., 2013,
Serasinghe et al., 2015). However, the
activation of DRP1 by oncogenic MAPK
signaling that occurs during cellular
transformation is regulated in the
majority of samples (Serasinghe et al.,
2015). In addition, DRP1S616℗ is mar-
kedly enhanced in BRAFV600E-positive
dysplastic nevi and melanomas. This
activation correlates with the survival of
BRAFV600E cancer cells following treat-
ment with targeted therapies (Serasinghe
et al., 2015). Although there is also a
subset of BRAFV600E-positive lesions
that are negative for DRP1S616℗
(Figure 1c), recent studies suggest that
there are alternative mechanisms to
induce mitochondrial hyperfragmenta-
tion and subsequent apoptotic resis-
tance through the mitochondrial
dynamics machinery (Renault et al.,
2015). Collectively, these efforts suggest
that studying DRP1, and potentially other
proteins involved in orchestrating mito-
chondrial dynamics and function, may
offer a unique perspective to better
understand melanoma development,
diagnosis, and treatment.
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Figure 2. Inhibition of DRP1 suppresses BRAFV600E melanoma cell growth and survival. (a) A375 and SK-MEL-28 cells were treated with PLX-4032
(1 μM) or GSK-1120212 (10 nM) for 8 hours, and lysates were western blotted for indicated proteins. ERK℗ is shown as a positive control for drug sensitivity.
Multiple DRP1 isoforms explain the presence of additional bands in the SK-MEL-28 DRP1 blots. (b) A375 cells were infected with control or Drp1 RNAi,
and proliferation was quantiﬁed for 96 hours. (c) A375 cells were infected with control or Drp1 RNAi, and lysates were western blotted for indicated
proteins. (d) A375 cells were infected with control or Drp1 RNAi, cultured for 12 days, and stained. (e) Colony formation in d was quantiﬁed. (f) A375
cells were treated with mDIVI-1 (10 μM) for 8 hours and loaded with MitoTracker Green and Hoechst 33342 before live cell imaging. (g) A375 and
SK-MEL-28 cells were treated with mDIVI-1 (0, 5, 10, 25, 50, and 100 μM) for 48 hours before AnnexinV-ﬂuorescein isothiocyanate analysis. All data are
representative of at least triplicate experiments and reported as ± SD, as required. Scale bars=25 μm.
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TO THE EDITOR
A mammary gland is a speciﬁc type
of apocrine gland located in the sub-
cutaneous fat of the breast (Ackerman
et al., 2007). The interaction between
receptor of activator nuclear factor
kappa-B (RANK) and its ligand RANKL
is the main mediator of progesterone-
induced proliferation of mammary
epithelial cells, and the activation of
this pathway promotes mammary
tumorigenesis (Bhatia et al., 2005;
Gonzalez-Suarez, 2011). Extramammary
Paget’s disease (EMPD) is an un-
common adenocarcinoma of apocrine
origin. It usually affects older patients
and is highly metastatic to other organs,
including bone (Shiomi et al., 2013).
On the basis of these ﬁndings, we
hypothesized that the interaction
between RANK and RANKL has a role
in the tumorigenesis of EMPD.
To test this hypothesis, we collected
archival formalin-ﬁxed parafﬁn-
embedded skin specimens and cryosec-
tions from EMPD patients (Supple-
mentary Table S1 and S2 online) for
immunohistochemical and immuno-
ﬂuorescence analysis. This study was
approved by the ethics committee of
Tohoku University Graduate School ofAccepted article preview online 27 May 2015; published online 18 June 2015
Abbreviations: Arg1, arginase 1; DC, dendritic cell; EMPD, extramammary Paget’s disease; LC,
Langerhans cell; MMP-7, matrix metalloprotease-7; RANK, receptor of activator nuclear factor kappa-B;
Treg, regulatory T cell
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